Clearance of fibrinogen and von Willebrand factor in serial double-filtration plasmapheresis

Journal of Clinical Apheresis

Volumn 18, Issue 2, 2003, Pages 67-70

  Lin, Su Mei ^a   Yeh, Jiann Horng ^a   Lee, Chin Cheng ^a   Chiu, Hou Chang ^a  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Coagulopathy; Double filtration plasmapheresis; Hypofi brinogenemia; Plasma exchange; Von Willebrand factor

Indexed keywords

AUTOANTIBODY; FIBRINOGEN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BLOOD FILTRATION; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE FILTRATION PLASMAPHERESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HEMOSTASIS; HUMAN; HYPOFIBRINOGENEMIA; IMMUNOPRECIPITATION; MALE; OUTCOMES RESEARCH; PLASMA CLEARANCE; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TECHNIQUE;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; FIBRINOGEN; FILTRATION; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PLASMAPHERESIS; VON WILLEBRAND FACTOR;

EID: 0041665085     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/jca.10052     Document Type: Article

References (15)

1. McLeod BC, Sniecinski I, Ciavarella D, Owen H, Price TH, Randels MJ, Smith JW. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 1999;39:282-288.
2. Over J, Sixma JJ, Bouma BN, Bolhuis PA, Vlooswijk RA, Beeser-Visser NH. Survival of 125Iodine-labeled factor VIII in patients with von Willebrand's disease. J Lab Clin Med 1981;97:332-344.
3. Borchiellini A, Fijnvandraat K, ten Cate JM, Pajkrt D, van Deventer SJ, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996;88:2951-2958.
4. Sadler JE, Davie EW. Hemophilia A, Hemophilia B, and von Willebrand disease. In: Stamatoyannopoulos G, Majerus P, Perimutter RM, Varmus H, editors. Chap 21, The molecular basis of blood diseases. 3rd ed. Philadelphia: W.B. Saunders. 2001. p 680-718.
5. Chirnside A, Urbaniak SJ, Prowse CV, Keller AJ. Coagulation abnormalities following intensive plasma exchange on the cell separator. Br J Haematol 1981;48:627-634.
6. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994;23:817-827.
7. Yeh JH, Chiu HC. Double filtration plasmapheresis in myasthenia gravis: analysis of clinical efficacy and prognostic parameters. Acta Neurol Scand 1999;100:305-309.
8. Yeh JH, Chiu HC. Coagulation abnormalities in serial double filtration plasmapheresis. J Clin Apheresis 2001:16:139-142.
9. Bithell TC. Blood coagulation. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, editors. Wintrobe's clinical hematology, 9th ed. Philadelphia: Lea and Febiger; 1993. p 566-577.
10. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987;69:1691-1695.
11. Orlin JB, Berkman EM. Partial plasma exchange using albumin replacement. Removal and recovery of normal plasma constituents. Blood 1980;56:1055-1059.
12. Keller AJ, Chirnside A, Urbaniak SJ. Coagulation abnormalities produced by plasma exchange on the cell separator with special reference to fibrinogen and platelet level. Br J Haematol 1979;42:593-603.
13. Volkin RL, Starz TW, Winkelstein A, Shadduck RK, Lewis JH, Hasiba U, Spero JA. Changes in coagulation factors, complement, immunoglobulins, and immune complex concentration with plasma exchange. Transfusion 1982;22:54-58.
14. Yeh JH, Chiu HC. Optimal volume of processed plasma and total number of selective plasmapheresis sessions in the treatment of patients with severe generalized myasthenia gravis. J Clin Apheresis 1999:14:177-180.
15. Yeh JH, Chiu HC. Comparison between double filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 2000;247:510-513.